- LexaGene Holdings (LXG) has sold a MiQLab ™ System to the Alpine Veterinary Hospital in Concord, California
- Alpine Veterinary Hospital provides a wide range of services including emergency and orthopedic surgeries in the Bay Area of California
- LexaGene CEO and Founder, Dr. Jack Regan will be presenting at three upcoming conferences
- The first is investor-focused, the second is about advancements in microfluidics, and the third is about bio-threat detection
- LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for on-site rapid testing
- LexaGene Holdings Inc. opened trading at C$0.71 per share
LexaGene Holdings (LXG) has sold a MiQLab ™ System to the Alpine Veterinary Hospital.
LexaGene CEO and Founder, Dr. Jack Regan, states, “Following up on last weeks’ sales news, I’m pleased to report we have sold another MiQLab System. We will be shipping this purchased system to the Alpine Veterinary Hospital in Concord, California.
Alpine Veterinary Hospital, led by Dr. Virk, provides a wide range of services including emergency and orthopedic surgeries in the Bay Area of California. Dr. Virk believes the MiQLab System offers the best solution for his hospital. We are excited that Alpine Veterinary Hospital sees that the future of animal care begins with the MiQLab System. We continue to gain momentum in veterinary health as we’ve generated multiple MiQLab sales leads from ACVIM Forum, which we attended last week, and from the hard work of our dedicated sales team.”
The company is also pleased to announce that Dr. Regan will be presenting at three upcoming conferences: the first is investor-focused, the second is about advancements in microfluidics, and the third is about bio-threat detection.
On Monday, June 14, Dr. Regan will speak at the Lytham Partners Summer 2021 Investor Conference. LexaGene management will also participate in one-on-one meetings throughout the event, which runs from June 14-16.
On Tuesday, June 15, Dr. Jack Regan will present as part of the ‘Microfluidic Hotseat’ at the Annual Microfluids Consortium. The consortium is hosted by the Centre for Business Innovation, a collaboration managing a portfolio around specific areas of business process and technology where members share information to pursue like-minded business and innovation goals. The title of Dr. Regan’s talk is, “Sample-to-Answer Pathogen Detection using Flow-Through Sample Preparation and Customized Multiplex PCR”
Lastly, on Thursday, June 17, Dr. Regan will be a featured speaker at the International Biothreat and Pathogen Detection Conference.
His presentation, “Rapidly Configurable Automate Multiplexed Pathogen Detection System for Novel Threat Detection” will focus on the ability of the MiQLab to be easily configured to detect multiple pathogens in a single sample as a critical measure in biosurveillance activities. Examples of MiQLab’s applications for biothreat surveillance and diagnostics will be featured.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense.
End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter the sample ID and press ‘Go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
LexaGene Holdings Inc. opened trading at C$0.71 per share.